292 related articles for article (PubMed ID: 26256294)
1. Retrospective public health impact of a quadrivalent influenza vaccine in the United States.
Crépey P; de Boer PT; Postma MJ; Pitman R
Influenza Other Respir Viruses; 2015 Aug; 9 Suppl 1(Suppl 1):39-46. PubMed ID: 26256294
[TBL] [Abstract][Full Text] [Related]
2. Impact of quadrivalent influenza vaccine on public health and influenza-related costs in Australia.
Jamotte A; Chong CF; Manton A; Macabeo B; Toumi M
BMC Public Health; 2016 Jul; 16():630. PubMed ID: 27449665
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness of Quadrivalent versus Trivalent Influenza Vaccine in the United States.
de Boer PT; Crépey P; Pitman RJ; Macabeo B; Chit A; Postma MJ
Value Health; 2016 Dec; 19(8):964-975. PubMed ID: 27987647
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of quadrivalent versus trivalent influenza vaccine in Taiwan: A lifetime multi-cohort model.
Yang MC; Tan EC; Su JJ
Hum Vaccin Immunother; 2017 Jan; 13(1):81-89. PubMed ID: 27624648
[TBL] [Abstract][Full Text] [Related]
5. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine.
Reed C; Meltzer MI; Finelli L; Fiore A
Vaccine; 2012 Mar; 30(11):1993-8. PubMed ID: 22226861
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of quadrivalent influenza vaccine in Spain.
García A; Ortiz de Lejarazu R; Reina J; Callejo D; Cuervo J; Morano Larragueta R
Hum Vaccin Immunother; 2016 Sep; 12(9):2269-77. PubMed ID: 27184622
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults.
Pépin S; Donazzolo Y; Jambrecina A; Salamand C; Saville M
Vaccine; 2013 Nov; 31(47):5572-8. PubMed ID: 24016810
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥18 years: a phase III, randomized trial.
Tinoco JC; Pavia-Ruz N; Cruz-Valdez A; Aranza Doniz C; Chandrasekaran V; Dewé W; Liu A; Innis BL; Jain VK
Vaccine; 2014 Mar; 32(13):1480-7. PubMed ID: 24486352
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of an inactivated quadrivalent influenza vaccine in children 6 months through 8 years of age.
Greenberg DP; Robertson CA; Landolfi VA; Bhaumik A; Senders SD; Decker MD
Pediatr Infect Dis J; 2014 Jun; 33(6):630-6. PubMed ID: 24445833
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of quadrivalent influenza vaccine in Hong Kong - A decision analysis.
You JH; Ming WK; Chan PK
Hum Vaccin Immunother; 2015; 11(3):564-71. PubMed ID: 25714506
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults.
Beran J; Peeters M; Dewé W; Raupachová J; Hobzová L; Devaster JM
BMC Infect Dis; 2013 May; 13():224. PubMed ID: 23688546
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of inactivated quadrivalent and trivalent influenza vaccines in children 18-47 months of age.
Rodriguez Weber MA; Claeys C; Aranza Doniz C; Feng Y; Innis BL; Jain VK; Peeters M
Pediatr Infect Dis J; 2014 Dec; 33(12):1262-9. PubMed ID: 25386965
[TBL] [Abstract][Full Text] [Related]
13. Influenza A/subtype and B/lineage effectiveness estimates for the 2011-2012 trivalent vaccine: cross-season and cross-lineage protection with unchanged vaccine.
Skowronski DM; Janjua NZ; Sabaiduc S; De Serres G; Winter AL; Gubbay JB; Dickinson JA; Fonseca K; Charest H; Bastien N; Li Y; Kwindt TL; Mahmud SM; Van Caeseele P; Krajden M; Petric M
J Infect Dis; 2014 Jul; 210(1):126-37. PubMed ID: 24446529
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness evaluation of quadrivalent influenza vaccines for seasonal influenza prevention: a dynamic modeling study of Canada and the United Kingdom.
Thommes EW; Ismaila A; Chit A; Meier G; Bauch CT
BMC Infect Dis; 2015 Oct; 15():465. PubMed ID: 26503131
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults.
Greenberg DP; Robertson CA; Noss MJ; Blatter MM; Biedenbender R; Decker MD
Vaccine; 2013 Jan; 31(5):770-6. PubMed ID: 23228813
[TBL] [Abstract][Full Text] [Related]
16. 4Flu - an individual based simulation tool to study the effects of quadrivalent vaccination on seasonal influenza in Germany.
Eichner M; Schwehm M; Hain J; Uphoff H; Salzberger B; Knuf M; Schmidt-Ott R
BMC Infect Dis; 2014 Jul; 14():365. PubMed ID: 24993051
[TBL] [Abstract][Full Text] [Related]
17. Impact of quadrivalent influenza vaccines in Brazil: a cost-effectiveness analysis using an influenza transmission model.
Crépey P; Boiron L; Araujo RR; Lopez JG; Petitjean A; de Albuquerque Luna EJ
BMC Public Health; 2020 Sep; 20(1):1374. PubMed ID: 32907562
[TBL] [Abstract][Full Text] [Related]
18. Trivalent and quadrivalent influenza vaccination effectiveness in Australia and South Africa: results from a modelling study.
Milne GJ; Halder N; Kelso JK; Barr IG; Moyes J; Kahn K; Twine R; Cohen C
Influenza Other Respir Viruses; 2016 Jul; 10(4):324-32. PubMed ID: 26663701
[TBL] [Abstract][Full Text] [Related]
19. From trivalent to quadrivalent influenza vaccines: Public health and economic burden for different immunization strategies in Spain.
Crépey P; Redondo E; Díez-Domingo J; Ortiz de Lejarazu R; Martinón-Torres F; Gil de Miguel Á; López-Belmonte JL; Alvarez FP; Bricout H; Solozabal M
PLoS One; 2020; 15(5):e0233526. PubMed ID: 32437476
[TBL] [Abstract][Full Text] [Related]
20. Public health impact and economic benefits of quadrivalent influenza vaccine in Latin America.
Jamotte A; Clay E; Macabeo B; Caicedo A; Lopez JG; Bricks L; Romero Prada M; Marrugo R; Alfonso P; Moreno Arévalo B; Franco D; Garcia Diaz L; Isaza de Molto Y
Hum Vaccin Immunother; 2017 Apr; 13(4):877-888. PubMed ID: 28118092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
